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Safety and Efficacy of Bivalirudin
Monotherapy in Patients With Diabetes
Mellitus and Acute Coronary Syndromes
A Report From the ACUITY
(Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Frederick Feit, MD, FACC,* Steven V. Manoukian, MD, FACC,† Ramin Ebrahimi, MD, FACC,‡
Charles V. Pollack, MD,§ E. Magnus Ohman, MD, FACC, Michael J. Attubato, MD, FACC,*
Roxana Mehran, MD, FACC,# Gregg W. Stone, MD, FACC#
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and Durham, North Carolina
Objectives We sought to evaluate clinical outcomes of patients with diabetes mellitus in the ACUITY (Acute Catheterization
and Urgent Intervention Triage Strategy) trial, overall and by treatment arm.
Background In the ACUITY trial, 13,819 patients with moderate- or high-risk acute coronary syndromes (ACS) were randomized to
heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibition (GPI), bivalirudin plus GPI, or bivalirudin
monotherapy. Compared with heparin plus GPI, bivalirudin monotherapy resulted in similar protection from ischemic
events with less major bleeding. Whether these results apply to patients with diabetes is unknown.
Methods We evaluated the impact of diabetes on 30-day net adverse clinical outcomes (composite ischemia [death, myocar-
dial infarction, or unplanned ischemic revascularization] or major bleeding), overall and by antithrombotic strategy.
Results Diabetes was present in 3,852 randomized patients (27.9%). Compared with nondiabetic patients, diabetic pa-
tients had higher 30-day rates of net adverse clinical outcomes (12.9% vs. 10.6%; p  0.001), composite isch-
emia (8.7% vs. 7.2%; p  0.003), and major bleeding (5.7% vs. 4.2%; p  0.001). Among diabetic patients,
compared with heparin plus GPI, bivalirudin plus GPI resulted in similar rates of net adverse clinical outcomes
(14.0% vs. 13.8%; p  0.89), while bivalirudin monotherapy resulted in a similar rate of composite ischemia
(7.9% vs. 8.9%; p  0.39) and less major bleeding (3.7% vs. 7.1%; p  0.001), yielding fewer net adverse clini-
cal outcomes (10.9% vs. 13.8%; p  0.02).
Conclusions Diabetic patients with ACS managed invasively have higher rates of composite ischemia and major bleeding.
Compared with treatment with heparin plus GPI, bivalirudin monotherapy provides similar protection from isch-
emic events with less major bleeding, resulting in a significant reduction in net adverse clinical outcomes.
(J Am Coll Cardiol 2008;51:1645–52) © 2008 by the American College of Cardiology Foundation
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than nondiabetic patients (2,3). A
recent meta-analysis supports the
clinical recommendation that ad-
ministration of a glycoprotein IIb/
IIIa inhibitor (GPI) should be
considered to be the standard of
care for diabetic patients with
ACS, given a significant reduction
in periprocedural ischemic events
and mortality at 30 days and 6
months (4). However, GPIs result
in an increased incidence of
hemorrhagic complications and
thrombocytopenia, both of which
ave been associated with early and late mortality in the ACS
opulation (5–9).
Bivalirudin, a direct thrombin inhibitor, is theoretically
n attractive alternative to unfractionated heparin (UFH)
r low-molecular-weight heparin (LMWH), given its
bility to inhibit both circulating and clot-bound throm-
in as well as thrombin-mediated platelet activation, its
inear pharmacokinetics, and short half-life (25 min)
10,11). An analysis of diabetic patients undergoing
lective or urgent percutaneous coronary intervention
PCI) in the REPLACE (Randomized Evaluation in PCI
inking Angiomax to Reduced Clinical Events)-2 trial
howed similar protection from ischemic events and signif-
cantly decreased minor bleeding with bivalirudin mono-
herapy compared with UFH plus a GPI (12).
Limited data exist in diabetic patients comparing bi-
alirudin, either alone or in combination with a GPI, to an
ndirect thrombin inhibitor (either UFH or enoxaparin)
lus a GPI in the ACS population. The ACUITY (Acute
atheterization and Urgent Intervention Triage Strategy) trial
as the first large-scale investigation to examine whether
linical outcomes of patients with moderate- or high-risk ACS
reated with all class I agents recommended in the American
ollege of Cardiology/American Heart Association guidelines
ould be further improved by a new pharmacologic regimen
sing bivalirudin (13). That trial demonstrated that bivalirudin
onotherapy was associated with a significant reduction in
0-day net adverse clinical outcomes (composite ischemia or
ajor bleeding) and significantly reduced major bleeding
ompared to heparin plus a GPI (13).
We sought in the present report to evaluate the pre-specified
ubgroup of diabetic patients in the ACUITY trial to assess
0-day clinical outcomes: 1) in patients with versus without
iabetes mellitus; and 2) in diabetic patients treated with
ivalirudin with and without routine GPI, compared with
hose treated with a heparin-based regimen plus routine GPI.
ethods
atient population, randomization, and study protocol.
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CABG  coronary artery
bypass graft surgery
GPI  glycoprotein IIb/IIIa
inhibitor
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TIMI  Thrombolysis In
Myocardial Infarctionhe design and primary results of the ACUITY trial have neen previously published (13,14). Briefly, 13,819 patients
ith ACS undergoing an invasive management strategy
ere randomly assigned in an open-label fashion equally to
of 3 antithrombotic regimens starting immediately after
andomization: a heparin (UFH or enoxaparin) plus a GPI
the control group), bivalirudin plus a GPI, or bivalirudin
onotherapy, in which GPI administration was permitted
nly for limited pre-specified indications. The UFH was
dministered as an intravenous (IV) bolus of 60 IU/kg body
eight plus an infusion of 12 IU/kg/h to achieve an
ctivated partial thromboplastin time of 50 to 75 s before
ngiography and an activated clotting time of 200 to 250 s
uring PCI. One milligram of enoxaparin per kg was
dministered subcutaneously (SC) twice daily before an-
iography. An IV bolus of an additional 0.3 mg/kg was
dministered before PCI if the most recent SC dose had
een given8 h earlier, or an IV bolus of an additional 0.75
g/kg was administered before PCI if the most recent SC
ose had been given 16 h earlier. Bivalirudin was begun
efore angiography, with an IV bolus of 0.1 mg/kg and an
nfusion of 0.25 mg/kg/h. Before PCI, an additional IV
olus of 0.5 mg/kg was administered, and the infusion was
ncreased to 1.75 mg/kg/h.
Patients assigned to the heparin plus GPI or bivalirudin
lus GPI arms were randomized again in a 2  2 factorial
esign to either upstream GPI initiation in all patients
mmediately after randomization or to deferred GPI initi-
tion for selective use in PCI patients only starting in the
atheterization laboratory. Crossover to upfront GPI ad-
inistration was permitted for patients assigned to deferred
PI initiation for refractory ischemia before angiography.
ccording to the Food and Drug Administration–approved
abeling, either eptifibatide or tirofiban was permitted for
pstream use and either eptifibatide or abciximab was
ermitted for deferred selective use. Dosages of all GPIs
ollowed the package insert and were adjusted for renal
mpairment.
Coronary angiography was performed within 72 h of
andomization with subsequent triage to PCI, coronary
rtery bypass graft surgery (CABG), or medical manage-
ent according to the standard of care. Aspirin was admin-
stered before angiography. Clopidogrel dosing and timing
ere left to the discretion of the investigators, but the
rotocol required 300 mg clopidogrel in all cases no later
han 2 h after PCI. The study was approved by the
nstitutional review board or ethics committee at each
articipating center, and all patients signed written in-
ormed consent. The authors had full access to the data and
ake responsibility for its integrity. All of the authors have
ead and agree to the manuscript as written.
nd points and statistical methods. The ACUITY trial
as powered for 3 primary 30-day end points: 1) net adverse
linical outcome (composite ischemia or major bleeding);
) composite ischemia, defined as death from any cause,
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April 29, 2008:1645–52 Bivalirudin in Patients With Diabetes and ACSarization for ischemia; and 3) major bleeding (non-CABG
elated), defined as intracranial, intraocular, or retroperito-
eal bleeding, access site hemorrhage requiring interven-
ion, 5 cm diameter hematoma, reduction in hemoglobin
f 4 g/dl without or 3 g/dl with an overt bleeding
ource, reoperation for bleeding, or blood product transfu-
ion. All primary and secondary end points were adjudicated
ith the use of source documents by a blinded clinical
vents committee.
Diabetes was defined as diagnosed hyperglycemia requir-
ng therapy with diet, oral agents, and/or insulin. The
resent analysis examined the baseline features and 30-day
utcomes: 1) of diabetic versus nondiabetic patients;
) within the diabetic cohort by randomized group compar-
ng each of the bivalirudin groups against the heparin plus
PI reference group; and 3) of insulin-treated diabetic
atients comparing the bivalirudin monotherapy group with
he heparin plus GPI group.
Although patients with diabetes in ACUITY represented
pre-specified subgroup for analysis, the ACUITY trial was
ot powered for formal noninferiority or superiority analysis
f this or any subgroup. Statistical comparisons were con-
ucted for the purpose of hypothesis generation. All anal-
ses used the intention-to-treat population. Medians and
nterquartile ranges are presented for continuous variables.
onparametric Wilcoxon rank sum test was used for com-
arison of continuous variables. Categoric variables were
ompared by the chi-square test. Relative risk and the
orresponding confidence intervals using normal approxima-
ion are presented for subgroups of the diabetic population.
Baseline Characteristics and Treatment Strateg
Table 1 Baseline Characteristics and Treatm
Diabetic Patien
(n  3,852)
Age, yrs, median (range) 64 (25–
75 yrs 690 (17.
Weight, kg, median (IQR) 88.5 (77–
Female 1,343 (34.
Renal insufficiency* 711/3,581 (19.
Current smoker 806/3,773 (21.
Prior myocardial infarction 1,353/3,736 (36.
Prior PCI 1,753/3,803 (46.
Prior CABG 913/3,846 (23.
Hypertension 3,211/3,840 (83.
Hyperlipidemia 2,649/3,777 (70.
High risk† 2,456/3,617 (67.
CK-MB/troponin elevation 1,947/3,518 (55.




Medical management 1,191 (30.
Values are expressed as n (%) unless otherwise specified. *Calculated
risk was defined as either CK-MB/troponin elevation or ST-segment dCABG  coronary artery bypass graft surgery; CK-MB  creatine kinase iso
coronary intervention.esults
iabetic status and outcome. In the ACUITY trial,
iabetes mellitus was present in 3,852 of 13,819 randomized
atients (27.9%). Baseline characteristics and treatment
trategies by diabetic status are detailed in Table 1. Com-
ared with nondiabetic patients, diabetic patients were more
ikely to be older, female, and to have higher body weight,
istory of hypertension, or hyperlipidemia. They were also
ore likely to have had a previous MI and to have
ndergone prior PCI or CABG. Conversely, diabetic pa-
ients were less likely to be smokers and were less commonly
lassified as high-risk upon enrollment (defined as elevated
reatine kinase isoenzyme MB fraction or troponin levels
nd/or ST-segment deviation). Angiography was performed
n 98.6% and 99.3% of diabetic and nondiabetic patients,
espectively; diabetic patients were similarly likely to un-
ergo PCI, more frequently managed by CABG, and less
ften managed medically than nondiabetic patients.
Clinical outcomes at 30 days in patients with versus
ithout diabetes are presented in Table 2. Diabetic com-
ared with nondiabetic patients had significantly higher
ates of composite ischemia (8.7% vs. 7.2%; p  0.003) and
ajor bleeding (5.7% vs. 4.2%; p  0.001), with a resultant
ncrease in net adverse clinical outcomes (12.9% vs. 10.6%;
 0.001). Among the components of the composite
schemia end point, death was significantly higher (2.1% vs.
.3%; p  0.001) in diabetic than in nondiabetic patients.
mpact of antithrombotic regimen on clinical outcomes
f diabetic patients. Baseline and procedural characteris-
ics of diabetic patients assigned to each of the 3 treatment
y Diabetic Status
Strategies by Diabetic Status
Nondiabetic Patients
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Bivalirudin in Patients With Diabetes and ACS April 29, 2008:1645–52rms are presented in Table 3. Between the 2 GPI treat-
ent groups, patients in the bivalirudin plus GPI group had
slightly lower incidence of prior MI or high-risk charac-
eristics. Among diabetic patients assigned to bivalirudin
onotherapy, 6.4% received provisional use of GPIs for
re-specified angiographic or clinical criteria. There were no
ther significant differences in any of the baseline demo-
raphic, clinical, or procedural characteristics between either
f the bivalirudin groups and the heparin plus GPI active-
ontrol group.
Clinical outcomes at 30 days are presented in detail in
able 4. Diabetic patients treated with bivalirudin mono-
herapy compared with those treated with heparin plus GPI
ad a significantly lower rate of net adverse clinical out-
omes (10.9% vs. 13.8%; p  0.02), driven primarily by a
eduction in non-CABG major bleeding (3.7% vs. 7.1%;
Clinical Outcomes at 30 Days by Diabetic Statu
Table 2 Clinical Outcomes at 30 Days by D
Net adverse clinical outcomes (primary end point)
Composite ischemia (primary end point)
Death
Myocardial infarction
Unplanned revascularization for ischemia
Major bleeding (non-CABG related) (primary end point)
Values are expressed as n (%) unless otherwise specified.
CABG  coronary artery bypass graft surgery.
aseline Characteristics of Diabetic Patients by Randomized Treat
Table 3 Baseline Characteristics of Diabetic Patients by Rando
Heparin (UFH or LMWH)
Plus GPI (n  1,298)
Bivaliru
(n 
Age, yrs, median (range) 65.0 (25–87)
75 yrs 239 (18.4)
Weight, kg, median (IQR) 88 (77–102)
Female 458 (35.3)
Insulin dependent 389 (30.0)
Renal insufficiency‡ 257/1,203 (21.4) 224/1
Current smoker 269/1,268 (21.2) 268/1
Prior myocardial infarction 474/1,261 (37.6) 408/1
Prior PCI 595/1,290 (46.1) 540/1
Prior CABG 317/1,295 (24.5) 275/1
Hypertension 1,095/1,293 (84.7) 1,045/1
Hyperlipidemia 880/1,272 (69.2) 877/1
High risk§ 848/1,216 (69.7) 788/1
CKMB/troponin elevation 662/1,182 (56.0) 627/1




Medical management 412 (31.7)
Aspirin 1,262 (97.2) 1
Prior thienopyridine exposure¶ 820 (64.4)
alues are expressed as n (%) unless otherwise specified. *p1  comparison between bivalirudin
onotherapy and heparin (unfractionated or enoxaparin) plus GPI. ‡Calculated creatinine cleara
levation or ST-segment deviation. Aspirin use before randomization or administration before angi
ose before angiography (in CABG and medically managed patients), or before PCI for PCI patients.
GPI  glycoprotein IIb/IIIa inhibitor; LMWH  low-molecular-weight heparin; UFH  unfractionated he 0.001), with no significant difference in the rate of
schemic events (7.9% vs. 8.9%; p  0.39), although a trend
as present toward a reduction in the occurrence of Q-wave
I with bivalirudin monotherapy (0.8% vs. 1.6%; p 
.05). Protocol-defined major bleeding, Thrombolysis In
yocardial Infarction (TIMI) major bleeding, TIMI minor
leeding, non-CABG minor bleeding, access site hemor-
hage, hemoglobin decreases of3 g/dl with overt bleeding,
hrombocytopenia, and blood transfusions all occurred sig-
ificantly less frequently in the bivalirudin monotherapy
roup compared with the heparin plus GPI group. In
ontrast, there were no significant differences in the clinical
utcomes of diabetic patients treated with bivalirudin plus a
PI compared with those treated with heparin plus a GPI
t 30 days. Event rates at 30 days for the 1,193 insulin-





(n  9,857) p Value
496 (12.9) 1,042 (10.6) 0.001
337 (8.7) 712 (7.2) 0.003
81 (2.1) 125 (1.3) 0.001
202 (5.2) 498 (5.1) 0.65
111 (2.9) 228 (2.3) 0.05






(n  1,287) p2 Value†
6–90) 0.54 64.0 (32–92) 0.09
8.6) 0.89 215 (16.7) 0.25
7–100) 0.25 90 (78–103) 0.10
4.5) 0.67 448 (34.8) 0.80
1.3) 0.48 408 (31.7) 0.34
9.1) 0.17 230/1,204 (19.1) 0.17
1.5) 0.85 269/1,260 (21.3) 0.93
3.3) 0.03 471/1,250 (37.7) 0.96
3.4) 0.18 618/1,270 (48.7) 0.20
1.7) 0.10 321/1,286 (25.0) 0.78
2.9) 0.21 1,071/1,286 (83.3) 0.33
0.9) 0.35 892/1,268 (70.3) 0.52
5.9) 0.04 820/1,205 (68.0) 0.37
3.9) 0.30 658/1,172 (56.1) 0.95
3.6) 0.95 408 (31.7) 0.27
6.3) 0.28 721 (56.0) 0.34
4.3) 0.89 160 (12.4) 0.21
9.4) 0.20 406 (31.5) 0.91
7.6) 0.52 1,252/1,285 (97.4) 0.75
4.4) 0.99 814 (65.1) 0.71
PI and heparin (unfractionated or enoxaparin) plus GPI. †p2  comparison between bivalirudin
0 ml/min using the Cockcroft-Gault equation. §High risk was defined as either CKMB/troponin
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April 29, 2008:1645–52 Bivalirudin in Patients With Diabetes and ACSompared with heparin plus a GPI were: net adverse clinical
utcomes (12.7% vs. 15.7%; p  0.23), composite ischemia
9.1% vs. 9.8%; p  0.74), and non-CABG major bleeding
4.7% vs. 8.2%; p  0.04).
Outcomes in numerous subgroups within the diabetic
ohort were explored (age 65 years, gender, pre-treatment
ith a thienopyridine in patients undergoing PCI, creati-
ine clearance 60 ml/min, high-risk presentation, revas-
ularization strategy) and are shown in Figure 1. The
ndings in the subgroups are consistent with those of the
verall diabetic patient population, with bivalirudin mono-
herapy resulting in no significant difference in rates of
schemia with less major bleeding than heparin plus GPI.
urthermore, there was no significant interaction within any
f these subgroups by treatment group on the rates of
schemic or bleeding outcomes.
iscussion
ajor findings. The present analysis reveals the following
ajor findings in diabetic patients with ACS undergoing an
nvasive management strategy: 1) adverse ischemic event
ates and prognosis are significantly worse than in nondia-
etic patients; 2) major bleeding complication rates are
ignificantly higher; 3) substitution of bivalirudin for
eparin in patients treated with routine use of a GPI-
ased strategy does not reduce ischemic event rates or
linical Outcomes at 30 Days in Diabetic Patients by Randomized
Table 4 Clinical Outcomes at 30 Days in Diabetic Patients by R
Heparin (UFH or LMW
Plus GPI
(n  1,298)
Net adverse clinical outcomes (primary end point) 179 (13.8)
Composite ischemia (primary end point) 115 (8.9)
Death/myocardial infarction 96 (7.4)
Death from any cause 27 (2.1)
Myocardial infarction 73 (5.6)
Q-wave 21 (1.6)
Non–Q-wave 52 (4.0)
Unplanned revascularization for ischemia 32 (2.5)




Access site 32 (2.5)
Hemoglobin decrease 3 g/dl with overt source 29 (2.2)
Hemoglobin decrease 4 g/dl with no overt source 9 (0.7)
Blood transfusion 58 (4.5)
Reoperation for bleed 1 (0.1)
Minor bleeding (non-CABG related)‡ 275 (21.2)
TIMI scale bleeding 97 (7.5)
TIMI major bleeding 31 (2.4)
TIMI minor bleeding 91 (7.0)
Thrombocytopenia§ 163 (12.6)
alues are expressed as n (%) unless otherwise specified. *p1  comparison between bivalirudin
onotherapy and heparin (unfractionated or enoxaparin) plus GPI. ‡Ecchymoses, epistaxis, gastroi
ells/mm3 in patients without baseline thrombocytopenia.
TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1 and 3.emorrhagic complications; and 4) the use of bivalirudin Ionotherapy (compared with heparin plus a GPI, the
stablished standard of care) results in a significantly
ower rate of net adverse clinical outcomes, owing to a
ignificant reduction in major bleeding complications
ith no significant reduction in ischemic efficacy. Re-
arding the latter treatment group comparison, we ob-
erved directionally similar outcomes to those of the
verall diabetic patient population in those requiring
reatment with insulin.
athopysiologic observations in diabetic patients: thera-
eutic implications. The metabolic abnormalities that char-
cterize diabetes, such as hyperglycemia and insulin resis-
ance, provoke molecular actions that contribute to vascular
ysfunction (15). Abnormal blood glucose levels have been
ssociated with systemic and coronary inflammation and a
rothrombotic state (16–18). Diabetic patients have in-
reased thrombin generation and higher levels of C-reactive
rotein, fibrinogen, von Willebrand factor, factor VII, factor
III, and platelet factor 4 (17,19). Increased expression of
latelet activation markers, such as P-selectin (which mediates
latelet-leukocyte interactions), and a higher proportion of
latelets expressing glycoprotein IIb/IIIa receptors, signify
nhanced platelet activity, inflammatory responses, and the
otential for thrombosis (20,21). Heparin also increases
latelet reactivity, particularly platelet expression of




(n  1,267) p1 Value*
Bivalirudin
Monotherapy
(n  1,287) p2 Value†
177 (14.0) 0.89 140 (10.9) 0.02
120 (9.5) 0.59 102 (7.9) 0.39
95 (7.5) 0.92 77 (6.0) 0.15
34 (2.7) 0.32 20 (1.6) 0.32
69 (5.4) 0.84 60 (4.7) 0.27
17 (1.3) 0.56 10 (0.8) 0.05
53 (4.2) 0.82 50 (3.9) 0.87
40 (3.2) 0.29 39 (3.0) 0.38
80 (6.3) 0.43 48 (3.7) 0.001
0 (0.0) 0.09 2 (0.2) 0.66
1 (0.1) 0.31 0 (0.0) —
9 (0.7) 0.41 1 (0.1) 0.06
36 (2.8) 0.55 12 (0.9) 0.003
23 (1.8) 0.45 13 (1.0) 0.01
10 (0.8) 0.78 10 (0.8) 0.80
50 (3.9) 0.51 30 (2.3) 0.003
0 (0.0) 0.32 2 (0.2) 0.56
283 (22.3) 0.48 158 (12.3) 0.001
93 (7.3) 0.90 48 (3.7) 0.001
27 (2.1) 0.66 11 (0.9) 0.002
89 (7.0) 0.99 46 (3.6) 0.001
150 (11.8) 0.58 127 (9.9) 0.03
PI and heparin (unfractionated or enoxaparin) plus GPI. †p2  comparison between bivalirudin
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Bivalirudin in Patients With Diabetes and ACS April 29, 2008:1645–52mic events in diabetic patients (22). Glycoprotein IIb/
IIa inhibitors added to heparin attenuate platelet–
latelet aggregate formation and reduce fibrinogen
inding to platelets, thereby decreasing the likelihood of
hrombus formation (21). These basic mechanisms pro-
Figure 1 Subgroup Analyses: 30-Day End Points for Diabetic Pa
The outcome data in subgroups, which are displayed as relative risk (RR) (solid sq
data in the overall diabetic population for treatment with bivalirudin monotherapy v
bypass graft; CKMB  creatine kinase isoenzyme MB fraction; CrCl  creatinine cide the pathophysiologic framework for the clinical sbservation that the addition of a GPI to heparin
mproves survival in diabetic patients presenting with
CS (4).
Bivalirudin inhibits both circulating and clot-bound
hrombin, with antiplatelet and anti-inflammatory effects
s by Treatment Group
) with 95% confidence interval (CI) (horizontal lines), are consistent with the
heparin plus a glycoprotein IIb/IIIa inhibitor (GPI). CABG  coronary artery
ce; PCI  percutaneous coronary intervention.tient
uares
ersus
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April 29, 2008:1645–52 Bivalirudin in Patients With Diabetes and ACSeparins, bivalirudin does not interact with platelet factor 4,
nd therefore the activity of bivalirudin in the vicinity of a
latelet-rich thrombus is not compromised (23). Because
ivalirudin also effectively inhibits thrombin-mediated
latelet activation at very low concentrations and decreases
-selectin expression, platelet-leukocyte aggregates and my-
loperoxidase release agents such as GPIs that block down-
tream aggregation of activated platelets may not be neces-
ary (10,23,24). Consistent with this hypothesis, the present
tudy supports the efficacy of bivalirudin monotherapy.
linical implications
ur findings confirm the earlier observations that among
atients with ACS, those with diabetes have worse clinical
utcomes than those without (2,3). Although we have cited
any pathophysiologic mechanisms that may play a role in
hese adverse outcomes, it is important to recognize that
iabetic patients in this trial were older and more often
emale and had a history of hypertension, hyperlipidemia,
rior MI, and prior CABG, all of which have been
ssociated with increased rates of ischemic and bleeding
vents (5,9,15–22). Our analysis of the effect of antithrom-
otic strategy on clinical outcomes expands upon that in
iabetic patients undergoing elective or urgent PCI in the
EPLACE-2 trial, in which bivalirudin monotherapy re-
ulted in similar protection from ischemic events at 1 year
nd a significant reduction in minor bleeding at 30 days
ompared with treatment with UFH plus a GPI (12). The
mproved clinical outcome for diabetic patients with ACS
eceiving bivalirudin monotherapy in the ACUITY trial
esulted from similar protection from ischemic events and a
arked reduction in major bleeding compared with a
eparin-based regimen combined with the routine use of
GPI. It is notable that these results were consistent across
broad spectrum of pre-specified subgroups, including
hienopyridine pretreatment in patients undergoing PCI.
hese benefits apply to diabetic patients with moderate- or
igh-risk ACS, whose management is guided by early
oronary angiography, regardless of revascularization strat-
gy or medical therapy. The recently revised American
ollege of Cardiology/American Heart Association guide-
ines provide a class IA recommendation for the adminis-
ration of an intravenous GPI for all patients presenting
ith unstable angina/non–ST-segment elevation MI, with
erhaps an enhanced benefit in patients with diabetes
ellitus (25). Our findings are particularly timely, because
hey indicate that bivalirudin monotherapy may be a suitable
lternative for diabetic patients.
Bleeding, which is the most common noncardiac com-
lication of ACS management, is associated with increased
hort- and long-term mortality (5,7,9,26). Even “mild”
leeding has been associated with a statistically significant
ncrease in an adjusted hazard for death and death or MI. In
ddition, recent data suggest that blood transfusion is also
n independent predictor of mortality (7).tudy limitations. There are certain limitations to this
nalysis. First, the ACUITY trial was not powered for any
ubgroup analysis, including one of the diabetic population.
herefore, it would not be appropriate to pre-specify a
ormal noninferiority or superiority hypothesis by random-
zed treatment group for the diabetic subset or, for that
atter, any other subset of the ACUITY trial, indicating
hat these results should be considered exploratory. How-
ver, the present analysis of nearly 4,000 diabetic patients
ndergoing an early invasive strategy for ACS is the largest
iabetic subgroup from a randomized trial and is larger than
he overall study populations of several trials which have
valuated similar end points in patients with ACS (27–30).
urthermore, these data were gathered prospectively, with
ll adverse events being adjudicated by an independent
linical events committee, blinded to treatment assignment.
econd, because this was an open-label study, results may
ave been affected by treatment bias. Third, the results of
he present study apply only to ACS patients in whom early
iagnostic angiography is planned. Finally, the current
nalysis presents 30-day outcomes only. Longer-term
ollow-up will add further perspective.
onclusions
iabetic patients with ACS managed with an early invasive
trategy have worse outcomes, in terms of both ischemic
vents and bleeding complications, compared with nondia-
etic patients, despite contemporary antithrombin and an-
iplatelet therapy. Among diabetic patients, treatment with
ivalirudin monotherapy rather than a heparin-based regi-
en plus GPI significantly reduces net adverse clinical out-
omes by providing similar protection from ischemic events
hile significantly reducing major bleeding complications. The
enefits of bivalirudin monotherapy were maintained in pa-
ients treated with insulin. These findings indicate that bi-
alirudin monotherapy is safe and efficacious for diabetic
atients with moderate- or high-risk ACS in whom early
oronary angiography is planned.
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